Anavex Life Sciences Corp. (AVXL) Financial Statements
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AVXLAnavex Life Sciences Corp.Follow AVXL — free
—
Price chart with a free account
- Market cap
- 123.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 23 Nov, in 30 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2006 Sep 06 | FY2007 Sep 07 | FY2008 Sep 08 | FY2009 Sep 09 | FY2010 Sep 10 | FY2011 Sep 11 | FY2012 Sep 12 | FY2013 Sep 13 | FY2014 Sep 14 | FY2015 Sep 15 | FY2016 Sep 16 | FY2017 Sep 17 | FY2018 Sep 18 | FY2019 Sep 19 | FY2020 Sep 20 | FY2021 Sep 21 | FY2022 Sep 22 | FY2023 Sep 23 | FY2024 Sep 24 | FY2025 Sep 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research & development | — | — | — | — | — | 2.6 | 2.7 | 0.3 | 0.7 | 2.3 | 7.3 | 10.7 | 13.3 | 22.3 | 25.2 | 33.0 | 37.9 | 43.7 | 41.8 | 37.6 | — | |
| Operating income | — | — | — | — | — | -6.2 | -4.3 | -2.1 | -3.0 | — | — | — | — | — | -31.1 | -42.0 | -51.0 | -55.8 | -52.9 | -51.4 | -17.4 | |
| Pre-tax income | — | — | — | — | — | — | — | -3.7 | -11.4 | -12.1 | -14.7 | -13.4 | -17.2 | -26.2 | -26.3 | -37.6 | -47.6 | -47.5 | -43.0 | -46.4 | -13.0 | |
| Income tax | — | — | — | — | — | — | — | — | -1.4 | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net income | -0.0 | -1.6 | -5.4 | -5.5 | -8.8 | -7.3 | -8.3 | -3.7 | -10.0 | -12.1 | -14.7 | -13.5 | -17.3 | -26.3 | -26.3 | -37.9 | -48.0 | -47.5 | -43.0 | -46.4 | -13.0 | |
| Diluted EPS ($) | — | — | — | — | — | -0.29 | -0.29 | -0.12 | -1.02 | -0.65 | -0.42 | -0.33 | -0.39 | -0.54 | -0.45 | -0.54 | -0.62 | -0.60 | -0.52 | -0.54 | -0.15 | |
| Diluted shares (mn) | — | — | — | — | — | 25.2 | 28.2 | 31.9 | 9.8 | 18.6 | 35.2 | — | — | — | — | 69.8 | 76.9 | 79.8 | 83.5 | 85.3 | — |
USD millions · SEC XBRL
Anavex Life Sciences Corp. — questions
- What is Anavex Life Sciences Corp.'s net income?
- -$13.0M over the twelve months to 2026-06-30.
- What are Anavex Life Sciences Corp.'s diluted earnings per share?
- $-0.15 over the twelve months to 2026-06-30.
Every figure on this page comes from Anavex Life Sciences Corp.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.